Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2025 16:30 ET | Source: Olema Oncology SAN FRANCISCO, April…
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
March 25, 2025 07:00 ET | Source: Predictive Oncology Inc. Company successfully…
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer
March 15, 2025 11:25 ET | Source: ZENTALIS PHARMACEUTICALS Azenosertib median duration…
IN8bio Announces Advanced Gamma-Delta () T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases
March 03, 2025 09:28 ET | Source: IN8bio, Inc Proprietary platform represents…
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
This is the second asset Menarini Group has inlicensed from Insilico Medicine…
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
This is the second asset Menarini Group has inlicensed from Insilico Medicine…
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
This is the second asset Menarini Group has inlicensed from Insilico Medicine…
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
This is the second asset Menarini Group has inlicensed from Insilico Medicine…
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
This is the second asset Menarini Group has inlicensed from Insilico Medicine…
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
This is the second asset Menarini Group has inlicensed from Insilico Medicine…